CIK 0001880438 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 820606654
- Phone
- (650) 331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $11,602
- in 1 filing
- Open-market sales, last 90 days
- $117,428
- in 4 filings, $104K under 10b5-1 plans
Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 94 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-19 | Wong Stephanie Director | Returned to the company · Stock Option (right to buy) | −24,999 | 0 | ||
| 2026-03-19 | Wong Stephanie Director | Grant or award · Stock Option (right to buy) | +10,362 | 10,362 | ||
| 2026-03-19 | Wong Stephanie Director | Returned to the company · Stock Option (right to buy) | −10,362 | 0 | ||
| 2026-03-19 | Wong Stephanie Director | Grant or award · Stock Option (right to buy) | +23,742 | 23,742 | ||
| 2026-03-19 | Wong Stephanie Director | Returned to the company · Stock Option (right to buy) | −23,742 | 0 | ||
| 2026-03-19 | Zakrzewski Joseph S Director | Grant or award · Stock Option (right to buy) | +99,999 | 99,999 | ||
| 2026-03-19 | Zakrzewski Joseph S Director | Returned to the company · Stock Option (right to buy) | −99,999 | 0 | ||
| 2026-03-19 | Zakrzewski Joseph S Director | Grant or award · Stock Option (right to buy) | +10,362 | 10,362 | ||
| 2026-03-19 | Zakrzewski Joseph S Director | Returned to the company · Stock Option (right to buy) | −10,362 | 0 | ||
| 2026-03-19 | Zakrzewski Joseph S Director | Grant or award · Stock Option (right to buy) | +23,742 | 23,742 | ||
| 2026-03-19 | Zakrzewski Joseph S Director | Returned to the company · Stock Option (right to buy) | −23,742 | 0 | ||
| 2026-03-19 | Eizen Joshua M See Remarks | Grant or award · Stock Option (right to buy) | +92,000 | 92,000 | ||
| 2026-03-19 | Eizen Joshua M See Remarks | Returned to the company · Stock Option (right to buy) | −92,000 | 0 | ||
| 2026-03-19 | Eizen Joshua M See Remarks | Grant or award · Stock Option (right to buy) | +50,150 | 50,150 | ||
| 2026-03-19 | Eizen Joshua M See Remarks | Returned to the company · Stock Option (right to buy) | −50,150 | 0 | ||
| 2026-03-19 | Spigelman Melvin K Director | Grant or award · Stock Option (right to buy) | +16,941 | 16,941 | ||
| 2026-03-19 | Spigelman Melvin K Director | Returned to the company · Stock Option (right to buy) | −16,941 | 0 | ||
| 2026-03-19 | Spigelman Melvin K Director | Grant or award · Stock Option (right to buy) | +10,362 | 10,362 | ||
| 2026-03-19 | Spigelman Melvin K Director | Returned to the company · Stock Option (right to buy) | −10,362 | 0 | ||
| 2026-03-19 | Spigelman Melvin K Director | Grant or award · Stock Option (right to buy) | +23,742 | 23,742 |
Page 4 of 10 · 191 trades